cover story
that price reduction is passed on to patients. He also said that the prices of all stocked stents will have to be revised according to the new ceiling price. The Minister laid stress that the landed price / manufacturing cost of imported BMS is Rs 5,415 and for DES is Rs 16,918, hence the ceiling prices have been set taking into account the ethical profit margins and R & D costs of each member of the supply chain of coronary stents.
On the other hand, the AiMeD’ s Rajiv Nath isn’ t convinced. He says,“ Hospitals will start demanding credit notes for loss made on inventory they hold. Manufactures will be asked to pay penalty for not acting overnight. If importers and manufacturers go to court ultimately public and patient are the one who will suffer. Ideally the implementation should have been from a cut-off date and next batch. The requirement of all stocks in market to be sold at revised price is impractical and unreasonable. Laws and rules should be reasonable and easy to follow.”
Meanwhile the NPPA is
22 BioVoiceNews | March 2017